Company news
Lyell Immunopharma, Inc. news in 2023
Lyell Immunopharma, Inc.'s news releases, calls and decks from 2023, newest first.
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
November 8, 2023
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
November 6, 2023
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
October 30, 2023
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
September 26, 2023
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform
September 10, 2023
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
September 10, 2023
Lyell Immunopharma to Participate in Upcoming Investor Conferences
August 30, 2023
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
August 7, 2023
Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer
July 4, 2023
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
May 3, 2023
Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
May 1, 2023
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
February 27, 2023
Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Decks in 2023
- Investor Presentation (September 2023)
Investor deck · 35 slides · Sep 11, 2023